Literature DB >> 12837933

Old dogs and new tricks: proteases, inhibitors, and cell migration.

Steingrimur Stefansson1, Daniel A Lawrence.   

Abstract

A new model for the actions of plasminogen activator inhibitors (PAIs) on cell migration may resolve the conflicting research data on these proteins in metastasis and angiogenesis. Results from two groups reveal a role for PAI-1 in promoting cycles of attachment and detachment of the cell from the extracellular matrix that is independent of its role as an enzymatic inhibitor of urokinase-type plasminogen activator (uPA). Through the formation of a complex of integrins, uPA and its receptor, and the clearance receptors of the low-density lipoprotein family, PAI-1 may promote endocytosis and recycling of these adhesion-controlling proteins, allowing cycling of cellular attachment and detachment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12837933     DOI: 10.1126/stke.2003.189.pe24

Source DB:  PubMed          Journal:  Sci STKE        ISSN: 1525-8882


  24 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

2.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

3.  Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation.

Authors:  Audrey M Bernstein; Sally S Twining; Debra J Warejcka; Edward Tall; Sandra K Masur
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

Review 4.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

5.  Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.

Authors:  Brandi R Whitley; Lea M Beaulieu; Jennifer C Carter; Frank C Church
Journal:  Gynecol Oncol       Date:  2006-10-30       Impact factor: 5.482

6.  Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing.

Authors:  François Maquerlot; Stephane Galiacy; Michel Malo; Christophe Guignabert; Daniel A Lawrence; Maria-Pia d'Ortho; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  SERPINE1 (PAI-1) is deposited into keratinocyte migration "trails" and required for optimal monolayer wound repair.

Authors:  Kirwin M Providence; Stephen P Higgins; Andrew Mullen; Ashley Battista; Rohan Samarakoon; Craig E Higgins; Cynthia E Wilkins-Port; Paul J Higgins
Journal:  Arch Dermatol Res       Date:  2008-04-02       Impact factor: 3.017

Review 8.  Serine proteases, inhibitors and receptors in renal fibrosis.

Authors:  Allison A Eddy
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

9.  Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer.

Authors:  Hiroyuki Yoshida; Wenjun Cheng; Jamie Hung; Denise Montell; Erika Geisbrecht; Daniel Rosen; Jinsong Liu; Honami Naora
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-14       Impact factor: 11.205

10.  Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.

Authors:  Jianbo Wu; Lin Peng; Grainne A McMahon; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.